CoChat
Sign Up
Cited by 121Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study

Open access
Javed, Zeeshan, Papageorgiou, Maria, Deshmukh, Harshal, Rigby, Alan S., Qamar, Unaiza, Abbas, Jehangir, Khan, Amer Y., Kilpatrick, Eric S., Atkin, Stephen L., Sathyapalan, Thozhukat·2019·Clinical Endocrinology
DOI 10.1111/cen.13968
Open this paper in CoChat — free accountOpen PDF

Abstract

Summary: Background: Empagliflozin is a sodium‐glucose‐cotransporter‐2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type‐2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS. Materials and methods: A randomized open‐label study was conducted in women with PCOS who were randomized to either empagliflozin 25 mg (n = 19) or metformin 1500 mg (n = 20) daily for 12 weeks. The main outcomes assessed were changes in anthropometric and body composition, hormonal and metabolic parameters. Results: Univariate analysis showed significant differences in weight (empagliflozin: −1.4 ± 3.2% vs metformin: 1.2 ± 2.3%; P = 0.006), body mass index (empagliflozin: −1.4 ± 3.2% vs metformin: 1.1 ± 2.2%; P = 0.006), waist circumference (empagliflozin: −1.6 ± 2.8% vs metformin: 0.2 ± 2.1%; P = 0.029) and hip circumference (empagliflozin: −2.0 ± 3.0% vs metformin: 1.1 ± 1.9%; P = 0.001), basal metabolic rate (empagliflozin: −1.8 ± 2.9% vs metformin: 0.1 ± 1.9%, P = 0.024) and fat mass (empagliflozin: −0.7 ± 4.9% vs metformin, 3.2 ± 5.0%; P = 0.023) between the empagliflozin and the metformin groups. These differences were confirmed in linear regression analysis after adjustment for relevant covariates. There were no significant changes in hormonal or metabolic parameters between both groups. Conclusion: There was a significant improvement in anthropometric parameters and body composition, in overweight and obese women with PCOS after 12 weeks of treatment with empagliflozin compared to metformin, although no changes were seen in hormonal or metabolic parameters.

Overview

Integrity signals

Registry

Crossref · 10.1111/cen.13968

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 38 references

Cited by

Sorted by citations

Items 101–120 of 120

Related

See all

Metadata

Authors
Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T.
Affiliations
  • University of Hull (GB)
  • Pakistan Kidney and Liver Institute and Research Center (PK)
  • Sidra Medical and Research Center (QA)
  • Weill Cornell Medical College in Qatar (QA)
Corresponding author
Sathyapalan, Thozhukat
ORCID
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2019-04-02
Volume
90
Issue
6
Pages
805-813
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
DOI
10.1111/cen.13968
OpenAlex
W2922516009
Cited by
121
References
38
Citations by year
2026: 12 · 2025: 20 · 2024: 18 · 2023: 20 · 2022: 22 · 2021: 16 · 2020: 11 · 2019: 1
FWCI
11.95
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Repository@Hull (Worktribe) (University of Hull) (submittedVersion, cc-by)
Funders
University of Hull
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
empagliflozin, polycystic ovary syndrome, metformin, SGLT2 inhibitors, body composition, weight loss, obesity, basal metabolic rate, fat mass, waist circumference, body mass index, insulin resistance, metabolic parameters, hormonal parameters, cardiovascular risk, women's health, drug comparison, anthropometry, SGLT1 inhibition, insulin sensitivity
MeSH terms
Adolescent, Adult, Anthropometry, Benzhydryl Compounds, Body Composition, Cardiovascular Diseases, Drug Administration Schedule, Female, Glucosides, Hormones, Humans, Life Style, Metformin, Middle Aged, Obesity, Polycystic Ovary Syndrome, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review